Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Exclusion Criteria

• •Has a pre-existing condition that is contraindicated including.
• •* Non-secretory or oligo-secretory MM
• •* Active plasma cell leukemia.
• •* Waldenström's macroglobulinemia.
• •* Primary amyloidosis.
• •* POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
• •* Active hepatitis B or C infection based on screening blood testing.
• •* Known active Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
• •* Significant cardiovascular disease.
• •* Major surgery within 4 weeks prior to first dose.
• •* Acute infections requiring antibiotic, antifungal or antiviral therapy within14 days prior to first dose.
• •* Peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to first dose.
• •* Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first dose.
• •* Any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study.